As tweeted last night by The Street.com’s Adam Feuerstein, the smug Mark Ahn is out at dreadful Galena Biopharmaceutical (GALE). Read more here.
The sell-side analysts whoring themselves out for banking business, like Needham’s moronic Chad Messer (read about him here and here) will now have to dust off the pads and kneel before newly promoted GALE CEO Mark Schwartz.
For those playing at home, the case to watch (or better yet send in an FOIA request) is:
In the Matter of Galena Biopharma, SEC File No. HO 12356 now known as “In the Matter of Certain Stock Promotions”
No wonder the GALE-eediots have been so silent recently.
THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.